18 Sep 2015 09:23
Bigger loss but positive drug trial results for Scancell Holdings
(ShareCast News) - Scancell Holdings's losses increased marginally in the year ended 30 April 2015. The cancer immunotherapy developer announced on Friday a wider loss of £2.414m from £2.222m last year. It comes as a result of expected additional expenditure on its SCIB1 ImmunoBody clinical trials
Read more